Gaurav Munj 2022-03-04T06:42:16+00:00 Press Releases Site - Investor Relations Nav Overview Press Releases Events and Presentations Financial Filings Stock Information Corporate Governance Contact Upcoming and Recent Events Corporate Presentation SEC Filings Stock Quote & Chart Historical Lookup Governance Documents Committees Year None202420232022 November 12, 2024 Biohaven Reports Third Quarter 2024 Financial Results and Recent Business Developments October 2, 2024 Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares October 1, 2024 Biohaven Announces Pricing of $250 Million Public Offering of Common Shares September 30, 2024 Biohaven Announces Proposed Public Offering of Common Shares September 30, 2024 Biohaven Initiates Pivotal Trial of Novel Investigational Drug for Treatment of Migraine September 23, 2024 Biohaven Achieves Positive Topline Results in Pivotal Study of Troriluzole in Spinocerebellar Ataxia (SCA) September 20, 2024 Biohaven Announces Conference Call to Discuss Topline Pivotal Study Results in Spinocerebellar Ataxia August 8, 2024 Biohaven Reports Second Quarter 2024 Financial Results and Recent Business Developments May 29, 2024 Biohaven Showcases Broad Innovative Portfolio and Pipeline Updates Across Multiple Therapeutic Areas including Immunology, Neuroscience, Metabolic Disorders and Oncology at Annual Investor R&D Day May 29, 2024 Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial Tumors Current page 1 Page 2 ► ► Displaying 1 - 10 of 18 BIOHAVEN (BHVN) Volume Market Cap 52 Week High 52 Week Low Minimum 15 minutes delayed. Source:
Year None202420232022 November 12, 2024 Biohaven Reports Third Quarter 2024 Financial Results and Recent Business Developments October 2, 2024 Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares October 1, 2024 Biohaven Announces Pricing of $250 Million Public Offering of Common Shares September 30, 2024 Biohaven Announces Proposed Public Offering of Common Shares September 30, 2024 Biohaven Initiates Pivotal Trial of Novel Investigational Drug for Treatment of Migraine September 23, 2024 Biohaven Achieves Positive Topline Results in Pivotal Study of Troriluzole in Spinocerebellar Ataxia (SCA) September 20, 2024 Biohaven Announces Conference Call to Discuss Topline Pivotal Study Results in Spinocerebellar Ataxia August 8, 2024 Biohaven Reports Second Quarter 2024 Financial Results and Recent Business Developments May 29, 2024 Biohaven Showcases Broad Innovative Portfolio and Pipeline Updates Across Multiple Therapeutic Areas including Immunology, Neuroscience, Metabolic Disorders and Oncology at Annual Investor R&D Day May 29, 2024 Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial Tumors Current page 1 Page 2 ► ► Displaying 1 - 10 of 18
November 12, 2024 Biohaven Reports Third Quarter 2024 Financial Results and Recent Business Developments
October 2, 2024 Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
September 30, 2024 Biohaven Initiates Pivotal Trial of Novel Investigational Drug for Treatment of Migraine
September 23, 2024 Biohaven Achieves Positive Topline Results in Pivotal Study of Troriluzole in Spinocerebellar Ataxia (SCA)
September 20, 2024 Biohaven Announces Conference Call to Discuss Topline Pivotal Study Results in Spinocerebellar Ataxia
August 8, 2024 Biohaven Reports Second Quarter 2024 Financial Results and Recent Business Developments
May 29, 2024 Biohaven Showcases Broad Innovative Portfolio and Pipeline Updates Across Multiple Therapeutic Areas including Immunology, Neuroscience, Metabolic Disorders and Oncology at Annual Investor R&D Day
May 29, 2024 Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial Tumors
